SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz as an early-stage community-driven project with an active developer, attracting attention from investors looking to move beyond typical pump-and-dump cycles. The community is actively pushing for mainstream platform visibility and increased trading volume to support their long-term goal of hitting significant market cap milestones.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is gaining momentum and trending as investors react to a strategic payroll infrastructure partnership with Stellar, fueling optimism for broader institutional adoption. The community is actively discussing the potential for future XRP collaboration and a possible Coinbase listing, with many using the current price consolidation as a strategic accumulation phase.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market capitalization as key drivers for significant growth potential. The community is actively discussing the token's upside, with many calling for increased volume and exchange listings to catalyze a major breakout.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its privacy-focused technology on the Base network, often citing support from Coinbase Ventures as a key catalyst. Enthusiasts are actively discussing the project's long-term potential for adoption and its mining and staking features, viewing it as a essential tool for digital sovereignty.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing heightened investor interest driven by a combination of its ongoing strategic pivot into pharmaceutical manufacturing, a fortified balance sheet, and market speculation regarding potential domestic supply chain contracts. Community discussion remains heavily focused on the company's turnaround progress, its status as a potential beneficiary of new pharmaceutical import tariffs, and bullish long-term value projections based on its infrastructure and asset base.

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Grace Therapeutics is gaining momentum as investors anticipate the upcoming PDUFA date for its drug candidate GTx-104. The community is focused on the potential for institutional accumulation and the stock's low float, with many discussing the strategic value of the asset as the company nears its regulatory catalyst.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The XRP community is currently polarized, caught between frustration over stagnant price action and excitement regarding Ripple's recent treasury platform integration with SWIFT. While some investors are bracing for further volatility and potential token supply unlocks, others are doubling down on long-term conviction, pointing to pending regulatory developments as the potential catalyst for institutional adoption.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened volatility and community debate as investors weigh the company's aggressive expansion and strong sales against concerns regarding its high valuation and inflationary pressures. Market participants are intensely focused on upcoming earnings, with active discussions split between bullish expectations for the brand's long-term growth and bearish caution over current price multiples.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors track its Phase 2 LOTUS trial progress and potential for its lead asset, AVTX-009, to impact the competitive immunology market. The community is actively discussing recent analyst coverage, including buy ratings and optimistic price targets, while maintaining a cautious dialogue regarding the company's long-term financing needs and historical volatility.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing heightened social media activity and trading volume driven by investor interest in its post-quantum cryptography features and recent institutional developments, including a shift toward US-based operations. The community remains deeply divided, with long-term holders expressing conviction in the project's technology and future adoption, while active traders continue to debate its recent price volatility and past performance relative to broader market trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 40.1% in the 4th quarter, according to its most recent Form 13F...

Best Pharmaceutical Stocks To Follow Today - April 3rd

Eli Lilly and Company, AbbVie, Bristol Myers Squibb, Pfizer, Regeneron Pharmaceuticals, Gilead Sciences, and Terns Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that re...

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Aberdeen Group plc Has $124.84 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Aberdeen Group plc raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.8% during the 4th quarter, according to the company in its most recent 13F filing...

TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions...

Bayer Advances AB-1002 Study, Highlights Pharma Growth Strategy

Bayer advances AB-1002 after AskBio completes mid-stage study enrollment, as its Pharma strategy and pipeline milestones drive long-term growth outlook.

Moody Lynn & Lieberson LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN

Moody Lynn & Lieberson LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent...

Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment

Bayer wins EU nod to expand Kerendia's use in heart failure, backed by strong phase III data, boosting a key drug driving growth and portfolio momentum.

Is ANIP Undervalued? How to Read Its 9.3x Forward P/E

ANI Pharmaceuticals trades at just 9.3x forward earnings, far below peers - raising a key question: is this a bargain or a signal of execution risks ahead?

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$761.85
Prev Close	$777.25
Open	$767.04
Dividend Yield	0.46%
50-Day Moving Average	$765.50
Beta	0.63
Avg. Volume	603,688.36
PE Ratio	18.33

52-Week High	$821.11
52-Week Low	$476.49
Market Capitalization	$80.53B
EPS (Annual)	$41.48
Price to Book	2.58
Revenue Per Employee	$930,752.76

REGN
Regeneron Pharmaceuticals, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest REGN News

REGNRegeneron Pharmaceuticals, Inc.